ASND
Ascendis Pharma A/S
There isn't enough reported data to score ASND yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ASND Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Under pressure | |
| Strong |
ASND's profitability and balance sheet are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its revenue.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ASND PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $267 | — |
| Cheap | 22x | $313 | +17% |
| Fair | 27x | $388 | +45% |
| Expensive | 29x | $428 | +60% |
Historical ranges are pointers, not guarantees.
ASND has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ASND Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ASND has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ASND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $14.54 | +$18.78 |
| Q4 2025 | -$4.18 | +$3.07 |
| Q3 2025 | -$4.24 | +$4.05 |
| Q2 2025 | -$5.04 | +$4.54 |
| Q1 2025 | -$6.45 | +$3.41 |
| Q4 2024 | -$7.25 | +$2.25 |
| Q3 2024 | -$8.29 | +$3.61 |
| Q2 2024 | -$9.58 | +$2.49 |
ASND has the stronger earnings trend. Trailing diluted EPS is up 125% for ASND versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
ASND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +347% |
| Q4 2025 | $274.9M | +42% |
| Q3 2025 | $237.3M | +269% |
| Q2 2025 | $175.6M | +339% |
| Q1 2025 | $112.1M | +5.3% |
| Q4 2024 | $193.2M | +26% |
| Q3 2024 | $64.2M | +20% |
| Q2 2024 | $40M | -24% |
ASND has the stronger quarterly revenue trend. Revenue is up 847% for ASND versus up 2.1% for NVO.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +142 points |
| Q4 2025 | 4% | +3.8 points |
| Q3 2025 | 5.2% | +172 points |
| Q2 2025 | -34% | +337 points |
| Q1 2025 | -103% | -52 points |
| Q4 2024 | 0.2% | +27 points |
| Q3 2024 | -167% | +113 points |
| Q2 2024 | -370% | -73 points |
ASND has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
ASND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$62.9M | +$76.8M |
| Q2 2024 | -$68.5M | +$102.1M |
| Q1 2024 | -$113.1M | +$51.5M |
| Q4 2023 | -$47.1M | +$114.5M |
| Q3 2023 | -$139.6M | -$26.3M |
| Q2 2023 | -$170.6M | -$28.3M |
| Q1 2023 | -$164.6M | -$15M |
| Q4 2022 | -$161.6M | -$19.3M |
ASND has the stronger cash trend. Its trailing FCF is up 36% versus its history, compared with NVO at down 14%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
ASND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +6.2M shares |
| 1 year | +11% | +6.8M shares |
| 3 years | +19% | +10.7M shares |
| 5 years | +24% | +13M shares |
| Available history | +42% | +19.6M shares |
ASND has 67M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $173.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $19.3M |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $2,222 |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ASND on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ASND Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
ASND has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ASND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 73.4 | Neutral |
ASND's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ASND PE vs Healthcare Sector
| Metric | ASND | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 4 | 29 | 25 pts below |
ASND is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ASND on valuation relative to its sector.
ASND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $240.8 | 11% above |
| 20 week MA | $250.3 | 6.7% above |
| 50 week MA | $235.2 | 14% above |
| 100 week MA | $202.9 | 32% above |
| 200 week MA | $160.1 | 67% above |
ASND has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ASND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.1 | $170.9 | +27% |
| 2021 | $170.9 | $139.3 | -18% |
| 2022 | $139.3 | $119.1 | -15% |
| 2023 | $119.1 | $126.0 | +5.8% |
| 2024 | $126.0 | $137.5 | +9.2% |
| 2025 | $137.5 | $209.0 | +52% |
| 2026 YTD | $209.0 | $267.1 | +28% |
ASND has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.